Full TIG­IT da­ta from Gilead, Ar­cus show low­er PFS rates than De­cem­ber read­out: #AS­CO23

CHICA­GO — Gilead and Ar­cus un­veiled a fuller snap­shot of a Phase II study test­ing their ex­per­i­men­tal can­cer im­munother­a­py com­bo that showed low­er pro­gres­sion-free sur­vival rates than its pre­vi­ous up­date, re­sults that are like­ly to spark fur­ther de­bate over the close­ly-watched clin­i­cal tri­al.

Last De­cem­ber, the an­ti-TIG­IT/an­ti-PD-1 com­bo, po­si­tioned as a first-line treat­ment for non-small cell lung can­cer, record­ed da­ta that drew mixed re­ac­tions. The lat­est analy­sis, pre­sent­ed Sat­ur­day af­ter­noon at AS­CO, in­clud­ed on­ly a hand­ful more pa­tients than the pre­vi­ous up­date, but PFS rates fell — in one co­hort by near­ly three months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.